Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQR309 pharmacokinetics with acid-reducing agents, intravenous/oral bioavailability, and CYP1A2 inhibition in healthy volunteers
NL-OMON43263Active, not recruiting
- Sponsor
- PIQUR Therapeutics AG
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of bimiralisib in cancer (3 arms), sponsored by PIQUR Therapeutics AG. Primary endpoint: Effect of acid-reducing agents on PQR309 pharmacokinetics. Started Jul 2016; status: active, not recruiting.
02
Drugs
bimiralisib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON43263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43263.